Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.
"Recent scientific and biomedical advances in precision medicine are driving cloud-based data and technology strategies, closing the gap in our ability to translate advances into clinically validated diagnostics and therapeutics," Elaine Johanson, acting director of health informatics in FDA's within the Office of the Chief Scientist, said in a statement. "PrecisionFDA contributes to an optimized and independent review process by making tools available that empower reviewers to assess the accuracy of analytic pipelines without requiring bioinformatics expertise and enabling effective sponsor-reviewer interaction on a secure, cloud-based platform."
"This project will combine the best elements of epigenetic research, bioinformatics, and CRISPR to create a tool that solves a real problem in the field of oncology," Bob Brown, chair of translational oncology in Imperial College's department of surgery and cancer, said in a statement. "The approach of epigenetic editing using CRISPR can potentially target precise epigenetic changes in a personalized manner to specific genes to make tumor cells more sensitive to chemotherapy drugs. Such targeting will avoid some of the non-specific side effects in cancer and normal cells caused by current epigenetic therapies."